Front-line Treatment of Philadelphia Positive (Ph+)/BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) With AP24534 (Ponatinib), a New Potent Tyrosine Kinase Inhibitor (TKI).
Latest Information Update: 23 May 2023
Price :
$35 *
At a glance
- Drugs Ponatinib (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Biomarker; Therapeutic Use
- Sponsors Incyte Corporation
- 19 May 2023 Results evaluating its efficacy ponatinib versus imatinib-based regimens using a matching adjusted indirect comparison from NCT00038610 , NCT00327678, NCT01424982 and NCT01641107 , published in the Advances in Therapy
- 18 Nov 2021 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 1 Nov 2019 to 31 Dec 2021.